logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

James Strauss

mary crowley cancer research
H指数:16
被引数:1,278

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors

一项关于modakafusp alfa单药及联合pembrolizumab治疗晚期或转移性实体瘤的Ib/II期研究

Frontiers in Oncology
IF3.3
2025-12-090
OAAI
David Gill; Charles L. Cowey; Gregory A. Daniels; David Sommerhalder; Raghad Abdul-Karim; John M. Kirkwood; Joanna Kolodney; Inderjit Mehmi; Rachel Roberts-Thomson; James Strauss; Sajeve Thomas; Eric Whitman; Yan Xing; Meredith McKean; Sabrina Collins; Cheryl Li; Gurpanna Saggu; Tian Chen; Shining Wang; Marina Lewis; Xavier Parot; Melissa Johnson
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies

DT2216（一种选择性BCL-xL降解剂）的首次人体I期研究，用于治疗复发/难治性实体恶性肿瘤患者

Journal of Hematology & Oncology
IF40.4
2025-11-120
OAAI
Daruka Mahadevan; Minal Barve; Devalingam Mahalingam; Jay Parekh; Michael Kurman; James Strauss; Larry Tremaine; Robert Hromas; Joshua Sills; John McCulloch; John Harkey; Stacy Suberg; Lisa Zimmerman; Guangrong Zheng; Daohong Zhou
Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers

GSK3326595的1b期和剂量扩展研究，PRMT5抑制剂作为单一疗法并与Pembrolizumab联合用于晚期癌症患者

Annals of Oncology
IF65.4
2025-09-090
PREAI
M.M. Gounder; P. Martin-Romano; A. Italiano; L.L. Siu; P.A. Cassier; G.S. Falchook; I.S. Lossos; D.W. Rasco; J.F. Hilton; M.A. McKean; F.L. Opdam; J. Strauss; M. De Jonge; J.S.P. Vermaat; T. Crossman; M. Zajac; A. Tarkar; F. Gonzalez Carreras; B.E. Kremer; O. Barbash; S. Segal; R. Parasrampuria; S. Postel-Vinay
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

TLR4激动剂GSK1795091的生物活性的制造依赖性变化及其对脂质A类似物开发的影响

CTS-CLINICAL AND TRANSLATIONAL SCIENCE
IF2.8
2022-09-127
OAAI
Steeghs, Neeltje; Hansen, Aaron R.; Hanna, Glenn J.; Garralda, Elena; Park, Haeseong; Strauss, James; Adam, Michael; Campbell, Gossett; Carver, Jennifer; Easton, Rachael; Mays, Katherine; Skrdla, Peter; Struemper, Herbert; Washburn, Michael L.; Matheny, Christopher; Piha-Paul, Sarina A.
PHARMACOKINETIC AND IMMUNOLOGIC DATA FROM A PHASE I STUDY OF THE CLICK CHEMISTRY-BASED THERAPY SQ3370 IN ADVANCED SOLID TUMORS AND SOFT-TISSUE SARCOMA PROVIDES PROOF-OF-CONCEPT FOR THE CAPAC PLATFORM
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2021-11-100
OA
Bhadri, Vivek; Subbiah, Vivek; Strauss, James; Chawla, Sant; Bui, Nam; Kwatra, Vineet; Weiss, Mia; Batty, Kathleen; Zakharian, Michael; Oneto, Jose Mejia; Srinivasan, Sangeetha; Yee, Nathan; Wilson, Rosalind; Saville, M. Wayne; Guminski, Alexander
Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels
SCIENCE ADVANCES
IF12.5
2021-10-0837
OAAI
Kurth, Isabel; Yamaguchi, Norihiro; Andreu-Agullo, Celia; Tian, Helen S.; Sridhar, Subhasree; Takeda, Shugaku; Gonsalves, Foster C.; Loo, Jia Min; Barlas, Afsar; Manova-Todorova, Katia; Busby, Robert; Bendell, Johanna C.; Strauss, James; Fakih, Marwan; McRee, Autumn J.; Hendifar, Andrew E.; Rosen, Lee S.; Cercek, Andrea; Wasserman, Robert; Szarek, Michael; Spector, Scott L.; Raza, Syed; Tavazoie, Masoud F.; Tavazoie, Sohail F.
Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
IF6.5
2021-01-013
OAAI
Bitterman, Danielle S.; Winter, Kathryn A.; Hong, Theodore S.; Fuchs, Charles S.; Regine, William F.; Abrams, Ross A.; Safran, Howard; Hoffman, John P.; Benson, Al B., III; Kasunic, Timothy; Mulcahy, Mary; Strauss, James F.; DiPetrillo, Thomas; Stella, Philip J.; Chen, Yuhchyau; Plastaras, John P.; Crane, Christopher H.
Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors
CANCER RESEARCH
IF16.6
2020-08-150
PRE
Mita, Monica; Mita, Alan; Hamilton, Erika; Falchook, Gerald S.; Postow, Michael; Chmielowski, Bartosz; Schilder, Russell J.; Strauss, James; Lim, Emerson; Pant, Shubham; Jain, Angela; Rixe, Oliver; Redman, Rebecca; Kim, Kevin B.; Dragovich, Tomislav; Harvey, R. Donald; Puzanov, Igor; Schneider, Nimisha; Deehan, Renee; Guennel, Tobi; Lin, Joe; Tavazoie, Sohail; Waltzman, Roger; Rowinsky, Eric; Szarek, Michael; Sridhar, Subhasree; Busby, Robert; Lebaka, Narayan; Andreu, Celia; Kurth, Isabel; Darst, David; Tavazoie, Masoud; Raza, Syed; Wasserman, Robert; Gonsalves, Foster C.

研究方向

暂未获取到该数据
H
Howard Safran
H 指数:54论文数:399被引数:1.4万
E
Erika Hamilton
H 指数:58论文数:843被引数:1.6万
S
Stephen J. Russell
H 指数:106论文数:854被引数:4.3万
M
Michael Szarek
H 指数:54论文数:289被引数:1.8万
J
Jaime R. Merchan
H 指数:40论文数:279被引数:1.4万
S
Sarina A. Piha‐Paul
H 指数:72论文数:1,085被引数:3.1万
A
Anthony J. Olszanski
H 指数:44论文数:421被引数:9,476
T
Trisha M. Wise‐Draper
H 指数:39论文数:497被引数:6,699
I
Inderjit Mehmi
H 指数:23论文数:123被引数:2,160
G
Gerald S. Falchook
H 指数:68论文数:810被引数:2.7万